| Followers | 73 |
| Posts | 3610 |
| Boards Moderated | 0 |
| Alias Born | 03/23/2013 |
Sunday, June 04, 2017 2:45:28 PM
Does shortening the trial by 6 months make a big enough difference for them to be forced to dilute, encounter ethical liability risk, and push the explosive growth of their company(and/or buyout) further into the future? Does this new patent change their strategy by mitigating their urge to complete vs halt the trial (assuming the results are positive)?
Another reason to "push their chips all in" (Re: R-IT) as Raf said, and follow through with this new patent.
Recent AMRN News
FEATURED Cannabix Technologies and Omega Laboratories Inc. Provide Positive Developments on Marijuana Breathalyzer Testing • Jul 11, 2024 8:21 AM
ECGI Holdings Enhances Board with Artificial Intelligence (AI) Expert Ahead of Allon Apparel Launch • ECGI • Jul 10, 2024 8:30 AM
Avant Technologies to Meet Unmet Needs in AI Industry While Addressing Sustainability Concerns • AVAI • Jul 10, 2024 8:00 AM
Panther Minerals Inc. Launches Investor Connect AI Chatbot for Enhanced Investor Engagement and Lead Generation • PURR • Jul 9, 2024 9:00 AM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
